One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
Perceptic describes itself as the AI operating system for drug development. Its legal entity is Perceptic Technologies Limited, with a registered office in London, and it was co-founded by Tilman Flock, Zaki Trache and Martin Copes, former Palantir life sciences executives according to Fortune.
The platform connects evidence, reasoning and decisions across the drug development lifecycle. It builds structured context from internal records, publications, clinical history and competitive intelligence, uses specialist AI workers to test assumptions, and lets teams approve and trace conclusions. It is infrastructure and model agnostic, and shows a SOC 2 Type 2 badge.
2. Highlighted features & specifications
- Evidence: builds structured context from internal records, publications, clinical history and competitive intelligence.
- Reasoning: specialist AI workers select evidence, test assumptions and identify gaps.
- Decisions: teams approve conclusions and carry them forward with traceable workflows.
- Model-agnostic design: infrastructure and models can be chosen by the customer.
- Security: SOC 2 Type 2 badge shown on the site.
3. Potential application
Evidence synthesis for licensing and in-licensing decisions at pharma companies. Selection of clinical trial indications. Building a data foundation for trial design at contract research organizations.
4. Benefits
Lets teams trace every claim to its source. Customers can bring their own data, hardware and models. Covers asset scouting, indication selection and clinical trial design in one platform. Decision workflows are traceable for review.
5. Market trends & opportunities
Pharma companies are adopting AI agents to speed up asset scouting and clinical development decisions. Vietnamese pharmaceutical manufacturers and clinical research organizations may use similar evidence platforms as they move toward generics innovation and trial participation.
6. Other information
Perceptic Technologies Limited, London, UK. Fortune reported a USD 12 million seed round led by Accel with Air Street Capital and Elder Gull on 26 May 2026, about 20 employees, and CSL as a named customer.
